
    
      Phase 1, open-label, dose-finding and cohort expansion study to determine the preliminary
      safety, tolerability, and pharmacokinetic (PK) profile of APR-246 (eprenetapopt) in
      combination with either ibrutinib or venetoclax + rituximab therapy in subjects with
      TP53-mutant NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.

      The study includes a safety lead-in portion followed by an expansion portion in subjects with
      R/R CLL and R/R MCL.
    
  